Clinical Trials
87
8 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1990
Active, not recruiting
2
2.3%
Completed
57
65.5%
Not yet recruiting
6
6.9%
Recruiting
7
8.1%
Suspended
1
1.1%
Terminated
2
2.3%
Unknown
11
12.6%
Withdrawn
1
1.1%
No approval data available
- Formosa Pharmaceuticals and Singapore Eye Research Institute announced a strategic collaboration to develop next-generation ophthalmic formulations using Formosa's APNT® nanoparticle technology. - The partnership aims to address unmet needs in corneal and ocular surface diseases by enhancing efficacy, bioavailability, and safety of topical ocular therapies. - Associate Professor Yu-Chi Liu will lead SERI's clinical research efforts, bringing expertise in corneal neuropathy and diabetic keratopathy to guide formulation development. - Formosa's APNT® platform reduces particle size of active pharmaceutical ingredients to stable nanoparticles, improving delivery of poorly soluble drugs to target tissues.
- Japan's Santen Pharmaceutical and Singapore Eye Research Institute have launched SONIC 2.0, a $21 million three-year research collaboration to develop first-in-class, disease-modifying therapies for vision-threatening eye diseases. - The initiative focuses on developing novel compounds for glaucoma, anti-scarring agents, improved myopia control treatments, and presbyopia therapies, aiming to generate two new clinical-stage candidates by 2028. - This collaboration builds on the successful SONIC 1.0 partnership that resulted in 13 research projects, six joint patents, and the first low-dose atropine drops approved for myopia treatment in Japan. - The research addresses critical unmet needs in Asia, where myopia affects 2.6 billion people worldwide and over 80% of Singapore's adult population, with prevalence projected to reach 69% across Asia by 2050.
- Enigma Health's AI platform reduced clinical audit time from 528 hours to 7 hours during a pilot at Singapore National Eye Centre, analyzing over 7,000 cataract surgeries. - The company signed MOUs with Roche to accelerate clinical trial recruitment and with ST Engineering to enhance AI-powered healthcare applications. - At KK Women's and Children's Hospital, the platform cut genetic reporting time from 30 minutes per report to seconds, processing 1,400 reports in an hour instead of weeks. - The AI model addresses the 40% of clinical trial costs attributed to patient recruitment by rapidly identifying eligible patients based on inclusion and exclusion criteria.
